Abiraterone Proves Efficient Against Prostate Cancer

Abiraterone Proves Efficient Against Prostate Cancer
shutterstock_171525971According to two recent studies, abiraterone, a drug for prostate cancer treatment, was found to increase survival in patients with advanced prostate cancer when given before chemotherapy. These encouraging results were published in Lancet Oncology. A previous study had found that patients that took abiraterone before chemotherapy decreased cancer progression time, but did not improve overall survival, with NICE guidelines rejecting abiraterone treatment before chemotherapy. The results of this study coincide with findings from a clinical trial, recently reported by researchers at The Institute of Cancer Research (ICR) and The Royal Marsden and published in Clinical Cancer Research, that found a subgroup of patients with advanced prostate cancer could benefit from abiraterone given prior chemotherapy. In fact, abiraterone is already in the HS recommendations as a drug prescribed to patients after chemotherapy. In the first study, the research team led by Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Honorary Consult
Subscribe or to access all post and page content.

Tagged , .

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

Leave a Comment

Your email address will not be published. Required fields are marked *